GlassScriptPhysician profile
Kassandra E Giglio
NPI 1629738422
$6,401.67
in general payments reported to CMS, 2019-2025
34 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $519 · 2023: $1,605 · 2024: $2,616 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,783 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,783.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.16 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $558.71 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $515.49 | 2022-2025 | |
| Braeburn INC. | $398.77 | 2023-2025 | Brixadi |
| Lilly USA, LLC | $375.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Collegium Pharmaceutical, INC. | $271.12 | 2022-2025 | Belbuca |
| Amgen INC. | $270.85 | 2023-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $232.88 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.94 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $207.13 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $187.00 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.49 | 2024-2025 | Caplyta |
| Astellas Pharma US INC | $171.79 | 2023-2024 | Veozah, Myrbetriq |
| Alkermes, INC. | $168.08 | 2023-2024 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $144.81 | 2022-2025 | Verquvo, Belsomra, Steglatro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $113.49 | 2024-2025 | Rexulti |
| Indivior INC. | $111.26 | 2023-2024 | Sublocade |
| Daiichi Sankyo INC. | $110.80 | 2024-2025 | Injectafer |
| Incyte Corporation | $99.99 | 2025 | |
| Glaxosmithkline, LLC. | $98.09 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $88.63 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $85.04 | 2022-2024 | |
| Shield Therapeutics INC | $80.62 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.54 | 2023-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $36.91 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $36.55 | 2023-2025 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $31.09 | 2022-2024 | Opdivo |
| Exact Sciences Corporation | $28.17 | 2024 | Cologuard Collection Kit |
| Seqirus USA INC | $21.64 | 2025 | Fluad, Flucelvax |
| Tonix Medicines, INC. | $21.17 | 2025 | Tonmya |
| Mylan Specialty L.P. | $17.66 | 2024 | Yupelri |
| Amarin Pharma, INC. | $17.40 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.55 | 2022 | |
| Viiv Healthcare Company | $14.57 | 2024 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kassandra Giglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.